Immunopharmacology最新文献_第9页

Role of complement receptors type 1 (CR1/CD35) and type 2 (CR2/CD21) in murine SLE 补体受体1型(CR1/CD35)和2型(CR2/CD21)在小鼠SLE中的作用

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/S0162-3109(00)80093-4

S.A. Boackle, J.M. Brown, V.M. Holers

引用次数: 0

Amyloid plaques in a transgenic mouse model of Alzheimer's disease (AD) contain complement components and pro-inflammatory cytokines 阿尔茨海默病(AD)转基因小鼠模型中的淀粉样斑块含有补体成分和促炎细胞因子

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/S0162-3109(00)80012-0

J.X. Yu , B.M. Bradt , K. Hsiao , N.R. Cooper

引用次数: 1

Characterisation of a transgenic pig line expressing high levels of CD46 表达高水平CD46的转基因猪品系的特性

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/S0162-3109(00)80187-3

B. Loveland, J. Milland, B. Thorley, D. Christiansen, P. Kyriakou, M. Lantéri, A. J. French, L. Williams, L. Baker, Brandon, R. Bellomo, I. Baldwin, D. Kahn, I. McKenzie

引用次数: 0

UVB-induced keratinocyte apoptosis in C1q deficient mice uvb诱导C1q缺陷小鼠角质细胞凋亡

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/S0162-3109(00)80048-X

MC Pickering, S Fischer, HT Cooke, MJ Walport, M Botto

引用次数: 0

Characterization of the human CR1-like transcript 人类cr1样转录物的表征

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/S0162-3109(00)80022-3

Daniel J. Birmingham, Christine M. Logar, Wei Chen

引用次数: 0

Should we use probiotics as supportive treatment for hereditary angioedema? 我们是否应该使用益生菌作为遗传性血管性水肿的支持治疗?

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/S0162-3109(00)80082-X

Kazimierz Madalinski, Hanna Jaworska, Hanna Gregorek

引用次数: 0

Phenotypes of complement knockouts. 补体基因敲除的表型。

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/s0162-3109(00)80298-2

V M Holers

{"title":"Phenotypes of complement knockouts.","authors":"V M Holers","doi":"10.1016/s0162-3109(00)80298-2","DOIUrl":"https://doi.org/10.1016/s0162-3109(00)80298-2","url":null,"abstract":"Although complete and partial complement deficiencies are well described in humans and several spontaneous animal models, many questions have remained regarding the exact role that these deficiency states play in the observed clinical manifestations. Likewise, many important mechanistic questions cannot be addressed using patients or spontaneously arising animal models of deficiency states. To provide additional insights and create readily manipulable experimental systems, over the last 5 years mice have been created by several groups in which specifically targeted insertional mutagenesis has resulted in complete deficiencies of complement activation proteins, receptors or regulatory proteins. Many surprising findings have already been made using mice derived from these strategies, and clinically relevant studies have begun to provide great insights into human deficiency states. This review includes an overview of these complement deficient mice and highlights some of the important findings that have resulted from their creation. A discussion of future experimental directions thought to be important by this author then follows and concludes the review.","PeriodicalId":13327,"journal":{"name":"Immunopharmacology","volume":"49 1-2","pages":"125-31"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s0162-3109(00)80298-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21745167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39

Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. 补体抑制剂:在抗炎治疗中一个复兴的概念。

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/s0162-3109(00)80299-4

A Sahu, J D Lambris

引用次数: 156

Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. 宿主识别和靶标分化因子H，补体替代途径的调节因子。

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/s0162-3109(00)80300-8

M K Pangburn

{"title":"Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement.","authors":"M K Pangburn","doi":"10.1016/s0162-3109(00)80300-8","DOIUrl":"https://doi.org/10.1016/s0162-3109(00)80300-8","url":null,"abstract":"Factor H is responsible for recognition of host cells and tissues and mediates discrimination among microbial pathogens during activation of the alternative pathway of complement (AP). Its unique structure of 20 SCR domains arranged in a flexible chain permits a variety of functional sites to interact with complement proteins and surface markers in a biological example of single-molecule combinatorial chemistry. In addition to the complement regulatory site located in the N-terminal four SCR domains, two other sites bind complement protein C3b and three sites appear to recognize a variety of polyanions that serve as host markers. Recent studies indicate that cooperativity among several C3b- and polyanion-binding sites influences the biological functions of factor H and that the degree of influence of each site varies on different cells. The engagement of one or more of the host marker recognition sites enables factor H to control activation of the AP. The absence of host-like markers allows AP activation, but many common pathogens have developed receptors for factor H or mimics of host markers of varying degrees of authenticity allowing them to escape detection by this innate defense system. Organisms using one or more of these evasive techniques include Neisseria gonorrhoeae, Streptococcus pyogenes, Yersinia enterocolitica, Trypanosoma cruzi, and the HIV virus.","PeriodicalId":13327,"journal":{"name":"Immunopharmacology","volume":"49 1-2","pages":"149-57"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s0162-3109(00)80300-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21745169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 187

Complement components of the innate immune system in health and disease in the CNS. 先天免疫系统的补体成分在健康和疾病的中枢神经系统。

Immunopharmacology Pub Date : 2000-08-01 DOI: 10.1016/s0162-3109(00)80302-1

P Gasque, Y D Dean, E P McGreal, J VanBeek, B P Morgan

{"title":"Complement components of the innate immune system in health and disease in the CNS.","authors":"P Gasque, Y D Dean, E P McGreal, J VanBeek, B P Morgan","doi":"10.1016/s0162-3109(00)80302-1","DOIUrl":"https://doi.org/10.1016/s0162-3109(00)80302-1","url":null,"abstract":"The innate immune system and notably the complement (C) system play important roles in host defense to recognise and kill deleterious invaders or toxic entities, but activation at inappropriate sites or to an excessive degree can cause severe tissue damage. C has been implicated as a factor in the exacerbation and propagation of tissue injury in numerous diseases including neurodegenerative disorders. In this article, we review the evidence indicating that brain cells can synthesise a full lytic C system and also express specific C inhibitors (to protect from C activation and C lysis) and C receptors (involved in cell activation, chemotaxis and phagocytosis). We also summarise the mechanisms involved in the antibody-independent activation of the classical pathway of C in Alzheimer's disease, Huntington's disease and Pick's disease. Although the primary role of C activation on a target cell is to induce cell lysis (particularly of neurons), we present evidence indicating that C (C3a, C5a, sublytic level of C5b-9) may also be involved in pro- as well as anti-inflammatory activities. Moreover, we discuss evidence suggesting that local C activation may contribute to tissue remodelling activities during repair in the CNS.","PeriodicalId":13327,"journal":{"name":"Immunopharmacology","volume":"49 1-2","pages":"171-86"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s0162-3109(00)80302-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21745171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 348